Author:
Stroes Erik,Colquhoun David,Sullivan David,Civeira Fernando,Rosenson Robert S.,Watts Gerald F.,Bruckert Eric,Cho Leslie,Dent Ricardo,Knusel Beat,Xue Allen,Scott Rob,Wasserman Scott M.,Rocco Michael
Funder
Amgen Inc
Amgen, Abbott Products, AstraZeneca, Merck, Sharp, and Dohme, and sanofi-aventis
Abbott Products, AstraZeneca, Merck, Sharp, and Dohme, Pfizer Australia, and Roche
Merck
Amgen, Novartis, and sanofi-aventis
Amgen and Eli Lilly
Subject
Cardiology and Cardiovascular Medicine
Reference22 articles.
1. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins;Baigent;Lancet,2005
2. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials;Cholesterol Treatment Trialists' (CTT) Collaboration;Lancet,2010
3. Discontinuation of statins in routine care settings: a cohort study;Zhang;Ann Intern Med,2013
4. Statin discontinuation in high-risk patients: a systematic review of the evidence;Gomez Sandoval;Curr Pharm Des,2011
5. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial;Visser;Eur Heart J,2012
Cited by
486 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献